RxDoctor Payments Data

Aubrey Paxson, DO

Internal Medicine · Houston, TXNPI 1750919346

Payments from drug & device makers

$2,124in general payments, 2019–2025

Across 112 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$501
  • Viiv Healthcare Company$307
  • Gilead$270
  • Exact Sciences$150
  • Pfizer$131
  • Lilly USA, LLC$129
  • plus $636 from 16 others

What the payments were for

  • Food & beverage$2,124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,124 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,970
Medicare patients
175
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$68,023
BiktarvyBictegrav/Emtricit/Tenofov Ala17$63,634
EliquisApixaban45$40,155
JardianceEmpagliflozin28$38,077
MounjaroTirzepatide28$28,331
FarxigaDapagliflozin Propanediol18$26,272
JanuviaSitagliptin Phosphate28$23,000
TrulicityDulaglutide13$16,272
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,067
EntrestoSacubitril/Valsartan14$9,517
Rosuvastatin Calcium157$2,555
Estradiol19$1,683
Atorvastatin Calcium191$1,587
Gabapentin90$1,542
Levothyroxine Sodium140$1,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$501$68,02364 claims
GileadBiktarvy$270$63,63417 claims
Lilly USA, LLCMounjaro, Trulicity$129$44,60441 claims
PfizerEliquis$131$40,15545 claims
Boehringer IngelheimJardiance$43$38,07728 claims
AstraZenecaFarxiga$114$26,27218 claims
MerckJanuvia$55$23,00028 claims
GSKTrelegy Ellipta$55$12,06715 claims
AbbVieSynthroid$48$94615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →